FrancophonIA/ELRC3.0 huggingface dataset:
English: Helixate NexGen 3000 IU contains (3000 IU / 5 mL) = 600 IU octocog alfa per mL after reconstitution.
Estonian: Helixate NexGen 3000 RÜ sisaldab (3000 RÜ/5 ml) = pärast lahustamist 600 RÜ alfaoktokogi ml kohta.
English: Helixate NexGen 500 IU contains (500 IU / 2.5 mL) = 200 IU octocog alfa per mL after reconstitution.
Estonian: Helixate NexGen 500 RÜ sisaldab (500 RÜ/2,5 ml) = pärast lahustamist 200 RÜ alfaoktokogi ml kohta.
English: Helixate NexGen 1000 IU contains (1000 IU / 2.5 mL) = 400 IU octocog alfa per mL after reconstitution.
Estonian: Helixate NexGen 1000 RÜ sisaldab (1000 RÜ/2,5 ml) = pärast lahustamist 400 RÜ alfaoktokogi ml kohta.
English: • One mL Helixate NexGen 250 IU contains approximately 100 IU (250 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Estonian: • 1 ml Helixate NexGen 250 RÜ sisaldab pärast süsteveega manustamiskõlblikuks muutmist ligikaudu 100 RÜ (250 RÜ / 2,5 ml) rekombinantset inimese VIII hüübimisfaktorit (INN:
English: How to store Helixate NexGen
Estonian: Kuidas Helixate NexGen'i säilitada
English: * Frequency is based on studies with all FVIII products which included patients with severe haemophilia A. PTPs = previously-treated patients, PUPs = previously-untreated patients
Estonian: PTP = previously treated patients, varem ravitud patsiendid, PUP =
English: • One mL Helixate NexGen 3000 IU contains approximately 600 IU (3000 IU / 5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Estonian: • 1 ml Helixate NexGen 3000 RÜ sisaldab pärast süsteveega manustamiskõlblikuks muutmist ligikaudu 600 RÜ (3000 RÜ / 5 ml) rekombinantset inimese VIII hüübimisfaktorit (INN:
English: Helixate NexGen 250 IU powder and solvent for solution for injection Helixate NexGen 500 IU powder and solvent for solution for injection Helixate NexGen 1000 IU powder and solvent for solution for injection Helixate NexGen 2000 IU powder and solvent for solution for injection Helixate NexGen 3000 IU powder and solvent for solution for injection Recombinant coagulation factor VIII (octocog alfa)
Estonian: Helixate NexGen 250 RÜ süstelahuse pulber ja lahusti Helixate NexGen 500 RÜ süstelahuse pulber ja lahusti Helixate NexGen 1000 RÜ süstelahuse pulber ja lahusti Helixate NexGen 2000 RÜ süstelahuse pulber ja lahusti Helixate NexGen 3000 RÜ süstelahuse pulber ja lahusti Rekombinantne VIII hüübimisfaktor (alfaoktokog)
English: België/Belgique/Belgien CSL Behring N.V.
Estonian: België/Belgique/Belgien
English: • One mL Helixate NexGen 1000 IU contains approximately 400 IU (1000 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Estonian: • 1 ml Helixate NexGen 1000 RÜ sisaldab pärast süsteveega manustamiskõlblikuks muutmist ligikaudu 400 RÜ (1000 RÜ / 2,5 ml) rekombinantset inimese VIII hüübimisfaktorit (INN:
English: • One mL Helixate NexGen 500 IU contains approximately 200 IU (500 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Estonian: • 1 ml Helixate NexGen 500 RÜ sisaldab pärast süsteveega manustamiskõlblikuks muutmist ligikaudu 200 RÜ (500 RÜ / 2,5 ml) rekombinantset inimese VIII hüübimisfaktorit (INN:
English: • One mL Helixate NexGen 2000 IU contains approximately 400 IU (2000 IU / 5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Estonian: • 1 ml Helixate NexGen 2000 RÜ sisaldab pärast süsteveega manustamiskõlblikuks muutmist ligikaudu 400 RÜ (2000 RÜ / 5 ml) rekombinantset inimese VIII hüübimisfaktorit (INN:
English: Helixate NexGen 250 IU powder for solution for injection Helixate NexGen 500 IU powder for solution for injection Helixate NexGen 1000 IU powder for solution for injection Helixate NexGen 2000 IU powder for solution for injection Helixate NexGen 3000 IU powder for solution for injection
Estonian: Helixate NexGen 250 RÜ süstelahuse pulber Helixate NexGen 500 RÜ süstelahuse pulber Helixate NexGen 1000 RÜ süstelahuse pulber Helixate NexGen 2000 RÜ süstelahuse pulber Helixate NexGen 3000 RÜ süstelahuse pulber
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL WITH 2.5 mL or 5 mL WATER FOR INJECTIONS
Estonian: RAVIMVORM JA PAKENDI SUURUS 1 viaal pulbriga süstelahuse valmistamiseks 1 viaal 2,5 ml süsteveega 1 viaal 5 ml süsteveega
English: Helixate NexGen 250 IU powder and solvent for solution for injection Helixate NexGen 500 IU powder and solvent for solution for injection Helixate NexGen 1000 IU powder and solvent for solution for injection Helixate NexGen 2000 IU powder and solvent for solution for injection Helixate NexGen 3000 IU powder and solvent for solution for injection
Estonian: Helixate NexGen 250 RÜ süstelahuse pulber ja lahusti Helixate NexGen 500 RÜ süstelahuse pulber ja lahusti Helixate NexGen 1000 RÜ süstelahuse pulber ja lahusti Helixate NexGen 2000 RÜ süstelahuse pulber ja lahusti Helixate NexGen 3000 RÜ süstelahuse pulber ja lahusti
English: Carefully check for particles and discoloration before administration.
Estonian: Enne manustamist kontrollige lahust visuaalselt tahkete osakeste ja värvimuutuse suhtes.
English: How Helixate NexGen is given
Estonian: Kuidas Helixate NexGen'i manustada
English: Paediatric population
Estonian: Patsientide erirühmad Lapsed
English: Enyglid repaglinide
Estonian: Enyglid repagliniid
English: Enyglid is taken before meals, normally up to 15 minutes before each main meal.
Estonian: Enyglidi võetakse enne sööki, tavaliselt kuni 15 minutit enne söögikorda.
English: It is available as tablets (0.5, 1 and 2 mg).
Estonian: Seda turustatakse tablettidena (0,5, 1 ja 2 mg).
English: The full EPAR for Enyglid can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Enyglidi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Enyglid
Estonian: Muu teave Enyglidi kohta
English: The European Commission granted a marketing authorisation valid throughout the European Union for Enyglid on 14 October 2009.
Estonian: Euroopa Komisjon andis Enyglidi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 14. oktoobril
English: The recommended starting dose is 0.5 mg.
Estonian: Soovituslik algannus on 0,5 mg.
English: If patients are transferred from another diabetes medicine, the recommended starting dose is 1 mg.
Estonian: Kui patsienti raviti enne muu diabeediravimiga, on soovituslik algannus 1 mg.
English: For more information about treatment with Enyglid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Enyglidiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: A doctor should regularly test the patient's blood glucose to find the lowest effective dose.
Estonian: Arst peab patsiendi vere glükoosisisaldust pidevalt kontrollima, et leida vähim efektiivne annus.
English: Enyglid is a ‘generic medicine'.
Estonian: Enyglid on geneeriline ravim.
English: The Committee recommended that Enyglid be given marketing authorisation.
Estonian: Komitee soovitas anda Enyglidi müügiloa.
English: Enyglid is a diabetes medicine that contains the active substance repaglinide.
Estonian: Enyglid on diabeediravim, mis sisaldab toimeainena repagliniidi.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Enyglid.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Because Enyglid is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Estonian: Et Enyglid on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Therefore, the CHMP's view was that, as for NovoNorm, the benefit outweighs the identified risk.
Estonian: Seetõttu otsustas inimravimite komitee, et nagu ka NovoNormi korral, ületab Enyglidi kasulikkus sellega kaasnevad riskid.
English: This means that Enyglid is similar to a ‘reference medicine' already authorised in the European Union (EU) called NovoNorm.
Estonian: See tähendab, et Enyglid on sarnane võrdlusravimiga NovoNorm, millel juba on Euroopa Liidus müügiluba.
English: Why has Enyglid been approved?
Estonian: Miks Enyglid heaks kiideti?
English: What are the benefits and risks of Enyglid?
Estonian: Milles seisneb Enyglidi kasulikkus ja mis riskid ravimiga kaasnevad?
English: The CHMP concluded that, in accordance with EU requirements, Enyglid has been shown to have comparable quality and to be bioequivalent to NovoNorm.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Enyglid võrdväärne kvaliteet ja bioekvivalentsus ravimiga NovoNorm.
English: This is a summary of the European public assessment report (EPAR) for Enyglid.
Estonian: See on ravimi Enyglid Euroopa avaliku hindamisaruande kokkuvõte.
English: What is Enyglid?
Estonian: Mis on Enyglid?
English: Because Enyglid is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, NovoNorm.
Estonian: Et Enyglid on geneeriline ravim, piirdusid inimuuringud katsetega, milles näidati Enyglidi bioekvivalentsust võrdlusravimiga NovoNorm.
English: How is Enyglid used?
Estonian: Kuidas Enyglidi kasutatakse?
English: It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) is not adequately controlled by diet, weight reduction and exercise.
Estonian: Enyglidi kasutatakse koos dieedi ja kehalise koormusega, et vähendada vere glükoosisisaldust (nn veresuhkrut) patsientidel, kelle hüperglükeemiat (vere liigset glükoosisisaldust) ei ole võimalik ainuüksi dieedi, kehakaalu alandamise ja kehaliste harjutustega piisavalt reguleerida.
English: How has Enyglid been studied?
Estonian: Kuidas Enyglidi uuriti?
English: Enyglid may also be used with metformin (another diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Estonian: Enyglidi tohib kasutada ka koos metformiiniga (samuti diabeediravim) II tüüpi diabeediga patsientidel, kellel ravi ainult metformiiniga ei anna rahuldavaid tulemusi.
English: Enyglid helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Estonian: Enyglid soodustab insuliini tekkimist kõhunäärmes söögi ajal ning seda kasutatakse II tüüpi diabeedi raviks.
English: Enyglid can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
Estonian: Enyglidi tohib kasutada ka nende II tüüpi diabeediga patsientide ravimiseks, kelle vere glükoosisisaldust saab tavapäraselt reguleerida dieediga, kuid kes dieediga reguleerimisele ajuti siiski ei allu.
English: What is Enyglid used for?
Estonian: Milleks Enyglidi kasutatakse?
English: Enyglid is used in adults who have type 2 diabetes.
Estonian: Enyglidi kasutatakse II tüüpi diabeediga (suhkurtõvega) täiskasvanute ravimiseks.
English: How does Enyglid work?
Estonian: Kuidas Enyglid toimib?
English: The marketing authorisation was renewed on 13 June 2005.
Estonian: Müügiluba pikendati 13. juunil 2005.
English: These effects are mild and temporary.
Estonian: Need nähud on kerged ja ajutised.
English: Ibaflin is available as tablets (30, 150, 300 and 900 mg) and as oral gels (3 and 7.5%).
Estonian: Ibaflini turustatakse tablettidena (30, 150, 300 ja 900 mg) ja suukaudsete geelidena (3 ja 7,5%).
English: This enzyme is only found in bacterial cells, and does not have a similar function in animal cells.
Estonian: Seda ensüümi leidub ainult bakterirakkudes ning loomarakkudes ei ole sellel samasugust funktsiooni.
English: The standard dose is 15 mg per kilogram body weight once a day for the length of time determined by your veterinarian.
Estonian: Tavapärane annus on 15 mg kehakaalu kilogrammi kohta üks kord päevas, ravi kestuse määrab loomaarst.
English: Ibaflin is given by mouth.
Estonian: Ibaflini manustatakse suu kaudu.
English: The use of ibafloxacin may result in an increase in the prevalence of resistant strains in the target species although this risk is likely to be less of a concern due to the treatment of individual animals with this product.
Estonian: Ibafloksatsiini kasutamise tulemusena võib suureneda resistentsete tüvede esinemine sihtliigil, kuigi üksikloomade ravimisel selle ravimiga on see oht tõenäoliselt väiksem.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) IBAFLIN EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE IBAFLIN Kokkuvõte üldsusele
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ibaflin to Intervet International B.V. on 13 June 2000.
Estonian: Euroopa Komisjon väljastas Ibaflini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Intervet International B.V.
English: A strain which is resistant to one type of fluoroquinolone will also be resistant to other members of the class of fluoroquinolones.
Estonian: Üht liiki fluorokinolooni suhtes resistentne tüvi on resistentne ka teiste fluorokinoloonide klassi kuuluvate ainete suhtes.
English: What is Ibaflin?
Estonian: Mis on Ibaflin?
English: The dose and duration of treatment depend on the nature and severity of the infection, the weight and species of the animal being treated, and the animal's response to treatment.
Estonian: Annus ja ravi kestus sõltuvad infektsiooni olemusest ja raskusest, ravitava looma kaalust ja liigist ning loomal tekkivast ravivastusest.
English: Why has Ibaflin been approved?
Estonian: Miks Ibaflin heaks kiideti?
English: Other information about Ibaflin:
Estonian: Muu teave Ibaflini kohta
English: Dogs are treated using the tablets, except for skin infection, where in addition to the tablets either strengths of the oral gel may be used.
Estonian: Koeri ravitakse tablettidega, välja arvatud nahainfektsiooni korral, mil võib kasutada lisaks tablettidele ükskõik kumma tugevusega suukaudset geeli.
English: In these studies, the effects of Ibaflin were compared with those of other antibiotics (marbofloxacin, enrofloxacin or amoxicillin/clavulanic acid).
Estonian: Neis uuringutes võrreldi Ibaflini toimet teiste antibiootikumidega (marbofloksatsiin, enrofloksatsiin või amoksitsilliin/klavulaanhape).
English: Cats are treated using the 3% oral gel.
Estonian: Kasse ravitakse 3% suukaudse geeliga.
English: Ibaflin is used to treat the infections in dogs and cats:
Estonian: Ibaflini kasutatakse koerte ja kasside nakkuste ravimiseks:
English: • upper respiratory tract infections caused by Staphylococci, E. coli and Klebsiella species.
Estonian: • ülemiste hingamisteede infektsioonid, mis on põhjustatud bakteritest Staphylococcus, E. coli ja Klebsiella.
English: However, the results were insufficient to support the use of Ibaflin in the treatment of urinary tract infections in cats.
Estonian: Samas ei piisanud uuringutulemustest, et toetada Ibaflini kasutamist kasside kuseteede infektsioonide raviks.
English: How does Ibaflin work?
Estonian: Kuidas Ibaflin toimib?
English: From data of two different clinical trials, comparable efficacy was shown between the Ibaflin gel formulations and a positive control to support the claims for skin (soft tissue infections - wounds, abscesses) and upper respiratory tract infections in cats for the oral gel formulations.
Estonian: Kahest erinevast kliinilisest uuringust saadud andmete põhjal tõendati Ibaflini geelvormide ja positiivse kontrollravimi efektiivsuse võrreldavust, millega toetati suukaudsete geelvormide näidustust kasside nahainfektsioonide (pehmete kudede infektsioonid - haavad, abstsessid) ja ülemiste hingamisteede infektsioonide raviks.
English: By blocking DNA gyrase, ibafloxacin prevents the bacteria from making DNA and stops them making proteins and growing, resulting in their death.
Estonian: DNA-güraasi blokeerimisega takistab ibafloksatsiin bakteritel DNA moodustamist ning peatab valkude tekke bakterites ja bakterite kasvu, mille tulemusena bakterid hävivad.
English: The indication for treatment of urinary infections in cats was not accepted.
Estonian: Näidustust kasside kuseteede infektsioonide raviks ei kiidetud heaks.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Ibaflin exceed the risks for the treatment of skin infections, and respiratory tract infections (upper tract) in dogs and cats, and acute, uncomplicated urinary tract infections in dogs, and recommended that Ibaflin be given a marketing authorisation.
Estonian: Veterinaarravimite komitee jõudis järeldusele, et Ibaflini kasulikkus teatavate naha ja (ülemiste) hingamisteede infektsioonidega ravimisel koertel ja kassidel ning ägedate, tüsistustega kuseteede infektsioonide ravimisel koertel ületab sellega kaasnevaid riske, ning soovitas anda Ibaflinile müügiloa.
English: Medical advice should be sought if the tablets are swallowed accidentally, particularly by a child.
Estonian: Kui inimene, eelkõige laps peaks tableti juhuslikult alla neelama, tuleb pöörduda arsti poole.
English: The tablets and oral gel were of comparable effectiveness in treating skin infections in dogs.
Estonian: Tabletid ja suukaudne geel olid koerte nahainfektsioonide ravimisel efektiivsuse poolest võrreldavad.
English: Comparable efficacy of the gel formulation to the tablet formulation was shown for dogs in a clinical trial.
Estonian: Geelvormi efektiivsust võrreldes tabletiga tõendati koertega läbi viidud kliinilises uuringus.
English: It is also used in dogs to treat acute (short-lived), uncomplicated infections of the urinary tract caused by Staphylococci, Proteus species, Enterobacter species, E. coli and Klebsiella species.
Estonian: Seda kasutatakse koertel ka bakterite Staphylococcus, Proteus, Enterobacter, E. coli ja Klebsiella põhjustatud ägedate (lühiajaliste) tüsistusteta kuseteede infektsioonide raviks.
English: Ibaflin tablets have been studied in dogs, looking at their effectiveness in treating skin, urinary tract and respiratory tract infections.
Estonian: Ibaflini tablettide kasutamist on uuritud koertel, vaadeldes ravimi efektiivsust naha, kuseteede ja hingamisteede infektsioonide ravimisel.
English: Salivation can also occur with the oral gel.
Estonian: Suukaudse geeli kasutamisel võib esineda ka süljevoolu.
English: Ibaflin oral gel is indicated in dogs for the treatment of skin infections (pyoderma - superficial and deep, wounds, abscesses).
Estonian: Ibaflini suukaudne geel on näidustatud koertel nahainfektsioonide (püodermiapindmine ja sügav, haavad, abstsessid) raviks.
English: Ibaflin contains ibafloxacin, which belongs to a class of medicines having an antibiotic action.
Estonian: Ibaflinis sisalduv ibafloksatsiin kuulub antibiootilise toimega ravimite klassi.
English: Ibafloxacin, is an antibiotic belonging to the class ‘fluoroquinolones'.
Estonian: Ibafloksatsiin on fluorokinoloonide klassi kuuluv antibiootikum.
English: What benefit has Ibaflin shown during the studies?
Estonian: Milles seisneb uuringute põhjal Ibaflini kasulikkus?
English: People who are hypersensitive (allergic) to quinolones should avoid any contact with Ibaflin.
Estonian: Ibafliniga kokkupuudet peavad vältima inimesed, kes on ülitundlikud (allergilised) kinoloonide suhtes.
English: How has Ibaflin been studied?
Estonian: Kuidas Ibaflini efektiivsust uuriti?
English: What are the side-effects associated with Ibaflin?
Estonian: Millised on Ibafliniga kaasnevad riskid?
English: The oral gel was also at least as effective as the comparator antibiotic (amoxicillin/clavulanic acid) in treating skin and upper respiratory tract infections in cats.
Estonian: Suukaudne geel oli kassidel naha ja ülemiste hingamisteede infektsioonide ravimisel vähemalt sama efektiivne kui võrdlusravimina kasutatud antibiootikum (amoksitsilliin/klavulaanhape).
English: Ibaflin tablets were at least as effective as the comparator antibiotics in treating skin, urinary tract and upper tract respiratory infections in dogs.
Estonian: Ibaflini tabletid olid koertel naha, kuseteede ja ülemiste hingamisteede infektsioonide ravimisel vähemalt sama efektiivsed kui võrdlusravimina kasutatud antibiootikumid.
English: The oral gel has been studied in cats looking at skin, respiratory tract and urinary tract infections.
Estonian: Suukaudse geeli kasutamist on uuritud kassidel naha, hingamisteede ja kuseteede infektsioonide ravimisel.
English: • skin infections, including shallow and deep ‘pyoderma', infected wounds and abscesses caused by bacteria such as Staphylococci, E. coli, Proteus species and Pasteurella species,
Estonian: • nahainfektsioonid, sealhulgas pindmine ja sügav püodermia, nakatunud haavad ja abstsessid,
English: What is Ibaflin used for?
Estonian: Milleks Ibaflini kasutatakse?
English: Diarrhoea, soft faeces, vomiting, dullness (lack of responsiveness) and anorexia (loss of appetite) occur with low frequency in dogs and cats given Ibaflin.
Estonian: Koertel ja kassidel, kellele manustatakse Ibaflini, esineb vähese sagedusega kõhulahtisust, pehmet rooja, oksendamist, loidust ja isutust.
English: This summary was last updated in November 2018.
Estonian: Kokkuvõtte viimane uuendus: november 2018.
English: Sufficient justification for extrapolation of these data to other strains was provided.
Estonian: Esitati piisavad põhjendused nende andmete ekstrapoleerimiseks teistele tüvedele.
English: No field studies were conducted.
Estonian: Väliuuringuid ei teostatud.
English: These strains belong to four different serotypes (groups) of the virus known as O, A, Asia 1 and SAT2, and are selected, depending on the epidemiological need, from the following eight strains: O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir and SAT2 Saudi Arabia.
Estonian: Tüved kuuluvad viiruse nelja eri serotüüpi (rühma) - O, A, Asia 1 ja SAT2 - ning need valitakse sõltuvalt epidemioloogilisest vajadusest järgmise kaheksa tüve hulgast: O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir ja SAT2 Saudi Arabia.
English: This was considered acceptable, given the laboratory data and taking into account that vaccination against foot-and-mouth disease is currently not permitted in the EU under legal controls on foot-and-mouth disease.
Estonian: Seda peeti vastuvõetavaks, arvestades esitatud laboriandmeid ja võttes arvesse, et vaktsineerimine suu- ja sõrataudi vastu on Euroopa Liidus praegu keelatud suu- ja sõrataudi seaduslike tõrjemeetmete kohaselt.
English: Further information can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/aftovaxpur-doe.
Estonian: Lisateave Aftovaxpur DOE kohta on ameti veebilehel: ema.europa.eu/medicines/veterinary/EPAR/aftovaxpur-doe.
English: When animals are vaccinated at 2 weeks of age, revaccination is recommended at 8 to 10 weeks.
Estonian: Kui loomad vaktsineeritakse kahe nädala vanuses, on soovitav nad 8-10 nädala vanuselt revaktsineerida.
English: The measure of effectiveness was the reduction in clinical signs of foot-and-mouth disease.
Estonian: Efektiivsuse näitaja oli suu- ja sõrataudi kliiniliste sümptomite vähenemine.
English: Revaccination is required every six months.
Estonian: Iga kuue kuu järel tuleb loomad revaktsineerida.